Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AN2 TherapeuticsANTX -4.63%23 EV-to-EBIT is -3.79 as of Aug. 13, 2026. GuruFocus rates ANTX with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 367 Biotechnology companies, AN2 Therapeutics ranks worse than 272479.29% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AN2 Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $97.35 Mil.
AN2 Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics EV-to-EBIT Related Terms
AN2 Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AN2 Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AN2 Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AN2 Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's EV-to-EBIT falls into.
AN2 Therapeutics's current Enterprise Value is $147.28 Mil.
AN2 Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics (ANTX) has a EV-to-EBIT of -3.79 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AN2 Therapeutics and its competitors. According to the industry distribution chart, AN2 Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry.
Is AN2 Therapeutics' EV-to-EBIT too high?
AN2 Therapeutics' current EV-to-EBIT is -3.79. Based on the distribution chart, AN2 Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AN2 Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' EV-to-EBIT compare to MENS and IVVD?
According to the Biotechnology industry distribution chart, AN2 Therapeutics ranks #999999 out of 367 companies for EV-to-EBIT. This places AN2 Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.42, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AN2 Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AN2 Therapeutics's current EV-to-EBIT is -3.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current EV-to-EBIT of -3.79. The current EV-to-EBIT is -3.79. AN2 Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current EV-to-EBIT is -3.79 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
23GF Score
Get the complete analysis for ANTX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANTX has been successfully added to your 
